Cargando…
Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers
Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is being rapidly incorporated into the clinical practice guidelines, including non–small cell lung and breast cancer...
Autores principales: | Cha, Yongjun, Kim, Sheehyun, Han, Sae-Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101775/ https://www.ncbi.nlm.nih.gov/pubmed/36915241 http://dx.doi.org/10.4143/crt.2023.446 |
Ejemplares similares
-
Utilization of Circulating Tumor Cells in the Management of Solid Tumors
por: Kurniali, Peter C., et al.
Publicado: (2023) -
Towards Circulating-Tumor DNA-Based Precision Medicine
por: Hironaka-Mitsuhashi, Ai, et al.
Publicado: (2019) -
Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
por: Lim, Yoojoo, et al.
Publicado: (2021) -
Patient‐derived organoids as a preclinical platform for precision medicine in colorectal cancer
por: Cho, Young‐Won, et al.
Publicado: (2022) -
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
por: Deveson, Ira W., et al.
Publicado: (2021)